Help Bring New Migraine Treatments to Light

If you’re living with frequent migraines and previous treatments haven’t worked, you may be able to help shape the future of migraine care.

Get Started

Clinical Research On the Aurora Migraine Study

Many individuals living with migraines do not experience meaningful relief from currently available preventive medications. The Aurora Study is evaluating an investigational drug (MEDI0618) to determine whether it can safely and effectively reduce the number of migraine days experienced each month.

Unlike existing treatments, MEDI0618 targets the PAR2-receptor, a key part of the pain pathway in migraine. By blocking this receptor, the investigational drug may prevent the cascade of events believed to cause migraine pain.

Schedule Your Appointment

Why Participate in Clinical Research?

By enrolling in a clinical trial like Aurora, you play a critical role in helping develop future therapies that could benefit thousands of others. Clinical research:

  • Helps evaluate whether new treatments are safe and effective
  • Offers access to investigational therapies before they are widely available
  • Advances our understanding of neurological conditions and patient outcomes

Is conducted under the supervision of licensed medical professionals and IRB-approved safety protocols

Who May Qualify for the Aurora Study?

You may be eligible if you:

  • Are 18 years or older
  • Experience 4 or more migraine days per month
  • Have not responded well to 3 or more currently available preventive migraine medications
Schedule Your Appointment

Why Participate in Clinical Research?

By enrolling in a clinical trial like Aurora, you play a critical role in helping develop future therapies that could benefit thousands of others. Clinical research:

  • Helps evaluate whether new treatments are safe and effective
  • Offers access to investigational therapies before they are widely available
  • Advances our understanding of neurological conditions and patient outcomes

Is conducted under the supervision of licensed medical professionals and IRB-approved safety protocols

Who May Qualify for the Aurora Study?

You may be eligible if you:

  • Are 18 years or older
  • Experience 4 or more migraine days per month
  • Have not responded well to 3 or more currently available preventive migraine medications
Schedule Your Appointment

What’s Involved in the Study?

The study lasts approximately 6 months and includes:

  1. Screening Period (up to 6 weeks)
    Includes lab work, physical exams, and health history review
  2. eDiary Headache Tracking (4 weeks)
    You'll use an electronic diary (eDiary) daily to track migraine activity and medication use
  3. Study Treatment Phase (12 weeks)
    Participants are randomly assigned to receive either the investigational drug or a placebo via injection every 2 weeks
  4. Follow-Up Period (10 weeks)
         Continued eDiary tracking and routine follow-up visits

Throughout the study, you will have up to 10 in-person visits and 6 scheduled phone calls to monitor your health and response to treatment.

Schedule Your Appointment

FAQs

What Are the Costs?

There is no cost to participate.

  • Study-related visits, medication, and testing are completely free
  • Reimbursement may be provided for reasonable travel or participation-related expenses


Is it Safe?

Your Safety is Our Priority

Every clinical study is reviewed and monitored by an Institutional Review Board (IRB) to ensure participant safety. Our research team is composed of trained neurologists and staff who will closely monitor your health throughout the study.

Can I stop participating once I’ve started?

Yes. Participation is completely voluntary. You may withdraw from the study at any time, for any reason, without affecting your future care.

Still Have a Question or Ready To Get Started?

Contact Us

Health Care Providers At Florida Neurology

Dr. Sam Shanmugham, MD

Dr. Ramit Panara, MD

Dr. Nitesh Shekhadia, MD

Robert Rahe, PA-C

Nidhi S. Patel, DNP, APRN, FNP-BC